Efficacy and Safety of Fenofibrate in Primary Hyperlipidemic Subjects

In order to evaluate the efficacy and safety of fenofibrate in Turkish people, 249 primary hyperlipidemic subjects, aged 31 - 74 years (mean 54±7), were treated with onee-a-day 250 mg controlled release fenofibrate following a lipidlowering diet. The efficacy and safety parameters were measured at baseline, on the 8th and the 12th weeks of therapy. After a treatment of 12 weeks, a decrease by 14.8% (p<0.0001), 13% (pKeywords: Hypercholesterolemia, hypertriglyceridemia, fenofibrate